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Topical Tretinoin, Another Failure
in the Pursuit of Practical
Chemoprevention for Non-Melanoma
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Peggy A. Wu1 and Robert S. Stern1
Given the high incidence of non-melanoma skin cancer (NMSC), a preventative
intervention would be desirable. Except for regular sunscreen use, the quest for
chemoprevention of NMSC in the general population has been unsuccessful.
Weinstock et al. assessed the effects of 0.1% topical tretinoin on NMSC. Like
earlier efforts at chemoprevention, this study failed to show therapeutic benefit.
Future successful preventative strategies will likely rely on short-term, intermittent
therapy or treatments used for other common indications.
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The final installment from the Veterans
Administration study of topical tretinoin
for the prevention of non-melanoma
skin cancer (NMSC) is now available
(Weinstock et al., this issue, 2012).
Perhaps not surprisingly, regular use of
tretinoin 0.1% cream versus placebo did
not demonstrate reduced risk of NMSC
in a high-risk population typical of those
enrolled in other chemoprevention
trials. Topical tretinoin joins the many
topical and oral therapies tested and
was ultimately found not to be effec-
tive in reducing NMSC risk.
More than 1 million new NMSCs are
diagnosed each year, making it the most
common cancer in the United States.
Basal cell carcinomas (BCCs) account
for about 80% of NMSCs, and most of
the remainder are squamous cell carci-
nomas (SCCs). Although generally not
life threatening, associated morbidity
may be substantial, particularly in rare
genetic syndromes such as xeroderma
pigmentosa (XP) and basal cell nevus
syndrome, and among solid-organ trans-
plant patients. Billions are spent each
year on the treatment of NMSCs, mak-
ing effective chemoprevention econom-
ically and medically attractive.
Chemoprevention considerations
The design of chemoprevention strate-
gies for reducing NMSC should consider
the target tumor (BCC or SCC), likely
mechanism of action, and intended
populations. SCCs often arise from a
precursor lesion, the AK, and risk is
increased with immunosuppression. In
contrast, no clinical precursor of BCC is
known. Our knowledge of the temporal
and dose relationship between exposure
to carcinogens and tumor development,
as well as the effects of immunosuppres-
sion on risk of NMSC, suggests that most
chemoprevention strategies are more
likely to be successful for SCC than for
BCC. High-risk persons in the general
population most likely to benefit from
chemoprevention would be patients
with a history of NMSC, particularly
SCCs, AKs, and/or those with fair skin
and substantial sun exposure history.
Factors associated with exceptionally
high risk include genetic mutations and
immunosuppression among persons
with phenotypic risk factors and sub-
stantial UV exposure. Depending on a
patient’s level of risk, the acceptable
cost, inconvenience, and consequences
of chemoprevention will vary. An oral
medication such as acitretin might be
reasonable for very high-risk transplant
patients. Its potential adverse effects and
modest efficacy argue against its case for
the typical high-risk dermatology patient
with a history of a limited number of
SCCs. Other important considerations
for evaluating chemoprevention include
patient adherence, ease of use, adverse
effects including medication interac-
tions, and cost. The optimal chemopre-
ventive agent would be effective,
without major adverse effects, easy to
use or useful for other common clinical
conditions, and inexpensive.
Chemoprevention contenders
Except for the inconvenience of appli-
cation and cost, regular use of sun-
screen comes close to such an ideal. In
Australian randomized controlled trials
(RCTs), the use of sunscreens reduced
the risk of SCC and AKs, but not of BCC
(Thompson et al., 1993; Green et al.,
1999; Darlington et al., 2003). The largest
and longest of these trials involved 1,621
participants divided into four groups
assigned different combinations of oral
beta-carotene or placebo in addition to
regular sunscreen use on the exposed
head, neck, arms, and hands, or discre-
tionary use of sunscreen. At 4.5 years,
the authors found a 40% decrease in
SCC incidence in areas of sunscreen use
incidence rate ratio (IRR) of 0.61 (95%
confidence interval, CI, 0.46–0.81); at
8 years, the IRR for SCCs equaled 0.65
(95% CI 0.43–0.98; Green et al., 1999;
van der Pols et al., 2006). A case–control
study suggested similar beneficial effects
in very high-risk organ transplant patients
(Ulrich et al., 2009). In certain high-risk
groups and children, routine sunscreen
use, at least on high-risk areas (face,
neck, arms), appears to be cost-effective
(Stern et al., 1986; Gordon et al., 2009).
Sunscreen use is relatively benign, but
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barriers to proper use that include cost,
cosmetic elegance, contact dermatitis,
and necessity of consistent and repeated
applications reduce adherence (Boggild
and From, 2003). Lack of significant effect
on BCC means that even if barriers to
use are overcome and theoretical risks
are discounted, widespread adoption of
sunscreen use in adults would likely
reduce NMSC incidence by about 10%.
Other promising candidates for skin
cancer chemoprevention include the
retinoids, whose activities include modu-
lating epithelial cell maturation and cuta-
neous immunity. Overall, large, blinded
RCTs have shown mixed results in the
high-risk general population (Levine
et al., 1997; Moon et al., 1997; Bath-
Hextall et al., 2007). Retinol, or vitamin
A, is available over the counter and has
a relatively benign side-effect profile at
modest doses. Although unconfirmed
by other studies, a double-blinded RCT
comparing 25,000 IU retinol daily with
placebo showed a modest and slight
statistically significant reduction of SCC
incidence with retinol, but no difference
in new BCCs (Moon et al., 1997).
Adverse symptoms and lab values were
comparable in both groups. Thus, for
the average, at-risk dermatology patient,
taking daily vitamin A might be slightly
effective in abrogating the risk of SCCs.
Beta-carotene has vitamin A and
antioxidative effects with few adverse
outcomes. However, large RCTs have
uniformly shown no benefit in the
prevention of AKs, BCCs, or SCCs
(Greenberg et al., 1990; Green et al.,
1999; Frieling et al., 2000; Darlington
et al., 2003). No association between
plasma beta-carotene and serum carote-
noids levels and risk and timing of
NMSC has been observed (Dorgan
et al., 2004; Schaumberg et al., 2004).
Many other antioxidants and supple-
ments, including selenium, vitamins A,
C, E, zinc, and grapeseed extract, have
been assessed as chemopreventive pos-
sibilities, with mixed results. A double-
blinded RCT comparing selenium
versus placebo found that those in the
selenium group were 17% more likely
to develop a new NMSC during the
13-year follow-up (hazard ratio¼1.17,
95% CI 1.02–1.34; Clark et al., 1996;
Duffield-Lillico et al., 2003). Other
studies of dietary intake of vitamins
A, C, E, folate, carotenoids, and NMSC
have shown no association (Fung et al.,
2002; Asgari et al., 2009, 2011).
Recently, there has also been growing
interest in the role of calcium and
vitamin D and cancer risk. However, a
post hoc analysis of the Women’s Health
Initiative double-blinded RCT did not
show an overall difference in incidence
of NMSCs or melanoma with calcium
and vitamin D supplementation (Tang
et al., 2011). There is little evidence
that the use of common vitamins and
supplements will reduce NMSC risk.
In an open trial conducted 20 years
ago, Kraemer et al. (1988) observed
substantial decreases in BCC and SCC
incidence in XP patients treated with
isotretinoin. However, a large double-
blind RCT of isotretinoin in veterans
with design and subjects similar to that
of Weinstock et al. (2012) found no
benefit and observed increased adverse
effects including elevation in total serum
triglycerides, mucocutaneous reactions,
and increased hyperostotic vertebral
changes in the treatment group (Tangrea
et al., 1992; Levine et al., 1997).
For very high-risk patients, systemic
aromatic retinoids, principally acitretin,
may have some benefit. Trials in renal
transplant patients have found that
25–30 mg per day of acitretin led to
decreased formation of SCCs, with inci-
dence decreased by about 40% in one
study (Bavinck et al., 1995; George
et al., 2002). In addition, a nested
cohort study of psoriasis patients treated
with psoralen plus UVA demonstrated a
20% risk reduction (adjusted IRR¼ 0.79,
95% CI 0.65–0.95) in the incidence
of SCCs. This beneficial effect was
limited to years in which retinoids
were being used and did not persist
in subsequent years (Bavinck et al.,
1995; Nijsten and Stern, 2003). There
were no differences in BCC incidence
(George et al., 2002; Nijsten and
Stern, 2003). Even for very high-risk
patients, the adverse effects of therapy
often preclude long-term use. For the
patient with a history of SCC or a
limited number of SCCs, the potential
risks of systemic retinoid therapy often
outweigh its likely benefit.
An ideal chemopreventive agent
would also be useful for another purpose
in the high-risk group, such as nonsteroi-
dal anti-inflammatory drugs (NSAIDs),
especially aspirin, and statins. Of at least
five associative studies of NSAIDs and
NMSC risk, only one has shown an asso-
ciated risk reduction (Butler et al., 2005;
Grau et al., 2006; Nunes et al., 2011;
Torti et al., 2011). An RCT of celecoxib
versus placebo found a significant asso-
ciated decrease in new NMSCs with use
(adjusted total risk ratio, RR¼0.41 95%
CI 0.23–0.72, P¼ 0.002). In contrast to
most positive chemopreventive trials, risk
reduction for SCC and BCC were equal,
and surprisingly no decrease in AKs was
observed (Elmets et al., 2010). Two large
retrospective cohort studies showed no
effect of statins on NMSC risk (Asgari
et al., 2009; Dore et al., 2009). Although
readily available and even if effective for
chemoprevention, NSAIDs are not with-
out potential side effects, including renal
insufficiency, hypertension, abnormal
bleeding, and cardiovascular or gastro-
intestinal symptoms. Therefore, unless
indicated for another purpose, for most
patients, the benefits of NSAIDs for
chemoprevention are unlikely to out-
weigh their risks.
Clinical Implications
 Numerous therapies including topical sunscreen, tretinoin, retinaldehyde,
oral retinol, beta-carotene, vitamins, isotretinoin, acitretin, non-steroidal
anti-inflammatory drugs, and statins have been tested as chemopreventive
agents for non-melanoma skin cancers.
Only regular use of sunscreen has been found to reduce incidence of
squamous cell cancers in the high-risk general population, and acitretin
has been found to temporarily reduce squamous cell cancers in very high-
risk patients.
 Chemoprevention of squamous cell carcinoma is more likely to be
successful than chemoprevention of basal cell carcinoma.
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The success of the systemic retinoids
and the effects of topical retinoids on
photoaging stimulated interest in the
potential of topical retinoids for skin
cancer prevention (Weiss et al., 1988).
Earlier small studies failed to provide
much encouragement, however, and
were limited by the absence of a
control group and heterogenous study
populations (Campanelli and Naldi,
2002). In this issue, Weinstock et al.
(2012) report on the primary results of a
phase III, multicenter, double-blinded
RCT of 1131 veterans with a history of
two previous NMSCs treated with
tretinoin 0.1% cream or placebo from
November 1998 to May 2004. The
incidence of AKs, BCCs, and SCCs was
comparable for treated patients and
placebo controls. Publishing important
but negative results is always difficult,
and may account for the 7-year gap
from completion of the study. This is
the 12th publication based on data from
this study. Earlier publications, some
in high-impact journals, were based
on post hoc analyses and confirmed no
association between NSAIDs, statin use,
and NMSC risk (Dore et al., 2009; Nunes
et al., 2011). However, angiotensin-con-
verting enzyme inhibitor and angiotensin
receptor blocker use was associated
with decreased risk of BCC (IRR¼ 0.61,
95% CI 0.50–0.76) and SCC (IRR¼ 0.67,
95% CI 0.52–0.87; Christian et al., 2008).
The most often cited and perhaps the
most notable of these publications
showed a statistically significantly increa-
sed mortality in tretinoin-treated patients
(Weinstock et al., 2009). This surprising
finding led to early termination of the
study.
Looking forward
Only two agents, sunscreen and sys-
temic retinoids, have been shown to
effectively prevent SCCs, and this study
appears to confirm that topical tretinoin
is not effective. However, focusing on
SCCs as opposed to NMSCs in general
may be more appropriate for future
study. Because of their biology, SCCs
may be more amenable to chemopre-
vention, and their greater morbidity may
lead to larger clinical impact. The lower
incidence of SCC necessitates larger
sample sizes. In a similar population to
Weinstock’s, a study powered to detect
a 33% decrease in SCC incidence, with
a type I error of 0.05 and a type II error
of 0.90, would require studying at least
1,800 participants for 5 years, more than
twice the number required to assess
chemoprevention if both SCC and BCC
are counted.
Some agents now used to treat actinic
keratosis and superficial NMSCs, such
as topical 5-fluorouracil, photodynamic
therapy (PDT), and imiquimod, offer
other avenues for future study of NMSC
risk reduction. Although effective in the
treatment of AKs, there have been no
large randomized trials investigating a
preventative regimen for topical 5-fluor-
ouracil. Preliminary studies on PDT
in preventing skin cancer in high-risk
patients and very high-risk transplant
patients produced mixed results; how-
ever, more recent studies have been
encouraging (de Graaf et al., 2006; Wulf
et al., 2006; Wennberg et al., 2008;
Apalla et al., 2010). Case letters and
early preliminary studies report decrea-
sed skin dysplasia in very high-risk
transplant patients and 450% reduction
of BCC incidence in a high-risk patient
with imiquimod use (Brown et al., 2005;
Czarnecki et al., 2009). These moda-
lities show promise as candidate chemo-
preventive agents, but cost and morbidity
are likely to limit their use to very high-
risk groups on limited body surface
areas. By continuing to investigate the
mechanisms of skin cancer formation,
encouraging avoidance of carcinogenic
exposures, and testing new potential
chemoprevention agents, we will build
the cornerstones of our hopes to reduce
NMSC incidence in the future.
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Capturing the Finer Points of Gene
Expression in Psoriasis: Beaming in
on the CCL19/CCR7 Axis
Laure Rittie´1 and James T. Elder1,2
Laser capture microdissection–coupled complementary DNA microarray analysis
is a powerful tool for studying minor cell populations in tissues. In this issue,
Mitsui et al. use this method to characterize the immune infiltrates that localize in
the dermis of psoriatic skin. They identify the T-cell activation regulators C–C
chemokine ligand 19 and C–C chemokine receptor 7 as potential mediators of
immune organization in psoriasis.
Journal of Investigative Dermatology (2012) 132, 1535–1538. doi:10.1038/jid.2012.134
Over the past decade, genetic, immuno-
logic, and transcriptome studies have been
used to identify key molecular path-
ways central to the pathogenesis of psori-
asis. Together, results from these studies
have converged in revealing alterations in
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